Literature DB >> 15657462

Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium.

Pierre M Barker1, Daniel J Gillie, Michael S Schechter, Bruce K Rubin.   

Abstract

Fourteen- and 15-member macrolide antibiotics are under investigation as potential therapeutic agents for cystic fibrosis (CF). The nonantibiotic mechanisms of action of these compounds in CF are not understood. We used nasal potential difference (NPD) measurements to test the effect of macrolides on airway epithelial ion (chloride, sodium) transport of CF mice and humans. We tested clarithromycin and azithromycin in mice, and clarithromycin in patients with CF. Baseline and post-treatment NPD was measured in two strains (C57Bl6 and BalbC) of CF transmembrane regulator "knockout" and littermate control mice, and in DeltaF508/DeltaF508 mice. In addition, NPD was measured in 18 human subjects with CF (17 DeltaF-508/DeltaF-508 and 1 DeltaF-508/other) who were undergoing a 12-month, randomized, double-blind crossover study of the effects of clarithromycin on pulmonary outcome in CF. Neither clarithromycin nor azithromycin affected ion transport characteristics of normal or CF nasal epithelium in either mouse or humans. We conclude that the apparent beneficial effects of macrolides on pulmonary outcome in CF are not mediated by their modulation of ion transport.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657462     DOI: 10.1164/rccm.200311-1508OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

Review 1.  Update in cystic fibrosis 2005.

Authors:  Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2006-05-01       Impact factor: 21.405

Review 2.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 3.  Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis.

Authors:  Sanjiv Sharma; Adam Jaffe; Garth Dixon
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 4.  Macrolide antibiotics for cystic fibrosis.

Authors:  Kevin W Southern; Pierre M Barker; Arturo Solis-Moya; Latifa Patel
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

5.  DETANO and nitrated lipids increase chloride secretion across lung airway cells.

Authors:  Lan Chen; Charles A Bosworth; Tristant Pico; James F Collawn; Karoly Varga; Zhiqian Gao; John Paul Clancy; James A Fortenberry; Jack R Lancaster; Sadis Matalon
Journal:  Am J Respir Cell Mol Biol       Date:  2008-02-28       Impact factor: 6.914

6.  Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.

Authors:  Rachida Legssyer; François Huaux; Jean Lebacq; Monique Delos; Etienne Marbaix; Patrick Lebecque; Dominique Lison; Bob J Scholte; Pierre Wallemacq; Teresinha Leal
Journal:  Respir Res       Date:  2006-10-25

7.  Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis.

Authors:  Wouter Beumer; Jim Swildens; Teresinha Leal; Sabrina Noel; Herma Anthonijsz; Geert van der Horst; Hester Kuiperij-Boersma; Marko Potman; Charlotte van Putten; Patricia Biasutto; Gerard Platenburg; Hugo de Jonge; Noreen Henig; Tita Ritsema
Journal:  PLoS One       Date:  2019-06-28       Impact factor: 3.240

8.  Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice.

Authors:  Emilie Lyne Saussereau; Delphine Roussel; Siradiou Diallo; Laurent Debarbieux; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.